Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: J Immunother. 2015 Jan;38(1):1–11. doi: 10.1097/CJI.0000000000000062

Figure 1. Pancreatic cancer Cy/GVAX therapy upregulates pancreatic tumor expression of PD-L1 in human & murine pancreatic ductal adenocarcinoma (PDA).

Figure 1

(A) Representative H&E staining and IHC with αPD-L1 antibody on resected PDA from unvaccinated patients and patients who received the Cy/GVAX vaccine therapy two weeks prior to surgical resection. (B) Immunofluorescence staining with αPD-L1 antibody and FITC conjugated secondary antibody in liver tumors after Panc02 hemispleen injection comparing mice treated with Cy/GVAX on day 4 and 7 after tumor inoculation (w/GVAX) against mice not receiving GVAX therapy (w/o GVAX) (upper panel). Livers were harvested two weeks after tumor cell inoculation. DAPI staining of nuclei is shown in lower panel.